Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE-2: WZTL-002 in Relapsed or Refractory Large B-cell Lymphoma
NCT06486051Phase 2Recruiting
- Sponsor
- Malaghan Institute of Medical Research
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atlacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Malaghan Institute of Medical Research. Primary endpoints: Complete Response Rate at 3 months and Immune Effector Cell-Associated Neurotoxicity Syndrome Rate at 3 months. Started Jul 2024; status: recruiting.
02
Drugs
atlacabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06486051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06486051.